BioArctic

BioArctic Net Change in Cash

The Net Change in Cash of BioArctic (BIOA B.ST) as of Nov 9, 2026 is 527.50 M SEK. In the previous year, Net Change in Cash was -98.64 M SEK — a change of -634.78% (higher).

Net Change in Cash

527.50 MSEK

YoY

-634.78%

Last updated:

Net Change in Cash of BioArctic is 2025 527.50 M SEK. Net Change in Cash of BioArctic was 2024 -98.64 M SEK. It decreases by -634.78% higher compared to the previous year.

The BioArctic Net Change in Cash history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Change in Cash
Date
Net Change in Cash
Jan 1, 2018
-193.06 M SEK
Jan 1, 2019
195.46 M SEK
Jan 1, 2020
-112.83 M SEK
Jan 1, 2021
-151.54 M SEK
Jan 1, 2022
-43.02 M SEK
Jan 1, 2023
-193.82 M SEK
Jan 1, 2024
-98.64 M SEK
Jan 1, 2025
527.50 M SEK
The BioArctic Net Change in Cash history
YEARNet Change in CashYoY
527.50 MSEK-634.78%
-98.64 MSEK-49.11%
-193.82 MSEK+350.54%
-43.02 MSEK-71.61%
-151.54 MSEK+34.30%
-112.83 MSEK-157.72%
195.46 MSEK-201.24%
-193.06 MSEK-146.20%
417.84 MSEK-27.80%
578.70 MSEK-3,149.48%
-18.98 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioArctic Stock analysis

What does BioArctic do? BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide. BioArctic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioArctic stock

Net Change in Cash of BioArctic is 527.50 M SEK in 2025.

Net Change in Cash of BioArctic changed from -98.64 M SEK to 527.50 M SEK, representing a -634.78% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Change in Cash BioArctic since 2006 – with annual values, charts, and detailed analysis.

Net change in cash is the total change in cash and equivalents during the period, combining operating, investing, and financing cash flows.

Net Change in Cash's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Change in Cash's BioArctic historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — BioArctic

All Key Metrics — BioArctic